Corcept Stock Analysis

CORT
 Stock
  

USD 28.70  0.37  1.31%   

The newest price gain of Corcept Therapeutics could raise concerns from private investors as the firm is trading at a share price of 28.70 on 575,000 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.88. The current volatility is consistent with the ongoing market swings in July 2022 as well as with Corcept Therapeutics unsystematic, company-specific events.
Continue to Trending Equities.
  
The Corcept Therapeutics stock analysis report makes it easy to digest most publicly released information about Corcept Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Corcept Stock analysis module also helps to analyze the Corcept Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Corcept Stock Analysis Notes

About 78.0% of the company shares are held by institutions such as insurance companies. The company had not issued any dividends in recent years. Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. Corcept Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 238 people. For more info on Corcept Therapeutics please contact Joseph Belanoff at 650 327-3270 or go to www.corcept.com.

Corcept Therapeutics Quarterly Cost of Revenue

1.32 Million

Corcept Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Corcept Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Corcept Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Corcept Therapeutics has a strong financial position based on the latest SEC filings
Over 78.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.bakersfield.com: Bragar Eagel Squire, P.C. Is Investigating Corcept, Hannon Armstrong, NIO, and Generac ... - The Bakersfield Californian

Corcept Therapeutics Upcoming and Recent Events

Earnings reports are used by Corcept Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Corcept Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report22nd of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End22nd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Corcept Largest EPS Surprises

Earnings surprises can significantly impact Corcept Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-05-01
2017-03-310.030.040.0133 
2016-11-01
2016-09-300.010.020.01100 
2015-11-05
2015-09-30-0.02-0.010.0150 
View All Earnings Estimates

Corcept Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Corcept Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Corcept Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Corcept Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of June 2022
Submission of Matters to a Vote of Security Holders
View
5th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
9th of March 2022
Unclassified Corporate Event
View
15th of February 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
14th of February 2022
Unclassified Corporate Event
View
11th of February 2022
Unclassified Corporate Event
View
9th of February 2022
Unclassified Corporate Event
View
4th of February 2022
Unclassified Corporate Event
View

Corcept Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Corcept Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corcept Therapeutics backward and forwards among themselves. Corcept Therapeutics' institutional investor refers to the entity that pools money to purchase Corcept Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Parallel Advisors LlcCommon Shares2.7 M64.6 M
Boston Trust Walden CorpCommon Shares1.3 M31.2 M
Td Asset Management IncCommon Shares960.4 K22.8 M
Aj Wealth Strategies LlcCommon Shares509.9 K12.1 M
Financial Advisory Service IncCommon Shares299.8 K7.1 M
Royce Associates LpCommon Shares280.4 K6.7 M
Trustcore Financial Services LlcCommon Shares208.8 KM
Note, although Corcept Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Corcept Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 3.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Corcept Therapeutics's market, we take the total number of its shares issued and multiply it by Corcept Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Corcept Profitablity

Corcept Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Corcept Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Corcept Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Corcept Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Corcept Therapeutics' profitability requires more research than a typical breakdown of Corcept Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 30.74 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 34.31 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.34.
Last ReportedProjected for 2022
Return on Investment 27.69  29.87 
Return on Average Assets 0.21  0.23 
Return on Average Equity 0.23  0.25 
Return on Invested Capital 0.30  0.31 
Return on Sales 0.34  0.37 

Management Efficiency

The entity has return on total asset (ROA) of 15.63 % which means that it generated profit of $15.63 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 25.03 %, meaning that it created $25.03 on every $100 dollars invested by stockholders. Corcept Therapeutics management efficiency ratios could be used to measure how well corcept therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to gain to 29.87 in 2022. Return on Average Assets is likely to gain to 0.23 in 2022. Corcept Therapeutics Liabilities Non Current is comparatively stable at the moment as compared to the past year. Corcept Therapeutics reported Liabilities Non Current of 409,000 in 2021. Tax Liabilities is likely to gain to about 422.5 K in 2022, whereas Total Liabilities is likely to drop slightly above 45.6 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 3.25  2.60 
Enterprise Value over EBIT 18.00  19.42 
Enterprise Value over EBITDA 17.19  18.55 
Price to Book Value 6.08  6.56 
Tangible Assets Book Value per Share 3.66  3.01 
Enterprise Value2.2 B1.8 B
Tangible Asset Value423.8 M343.9 M

Technical Drivers

As of the 7th of August, Corcept Therapeutics shows the Risk Adjusted Performance of 0.1985, downside deviation of 3.41, and Mean Deviation of 2.34. Corcept Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Corcept Therapeutics, which can be compared to its rivals. Please confirm Corcept Therapeutics standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Corcept Therapeutics is priced correctly, providing market reflects its regular price of 28.7 per share. Given that Corcept Therapeutics has jensen alpha of 0.4618, we suggest you to validate Corcept Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Corcept Therapeutics Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Corcept Therapeutics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.
.

Corcept Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corcept Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corcept Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Corcept Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sean Maduck over two weeks ago via Macroaxis 
Exercise or conversion by Sean Maduck of 5000 shares of Corcept Therapeutics subject to Rule 16b-3
Gary Robb over three weeks ago via Macroaxis 
Exercise or conversion by Gary Robb of 32677 shares of Corcept Therapeutics subject to Rule 16b-3
James Wilson over a month ago via Macroaxis 
Exercise or conversion by James Wilson of 300000 shares of Corcept Therapeutics subject to Rule 16b-3
David Mahoney over two months ago via Macroaxis 
Exercise or conversion by David Mahoney of 30000 shares of Corcept Therapeutics subject to Rule 16b-3
Murray Joshua M over two months ago via Macroaxis 
Acquisition by Murray Joshua M of 20000 shares of Corcept Therapeutics subject to Rule 16b-3
David Mahoney over two months ago via Macroaxis 
Exercise or conversion by David Mahoney of 30000 shares of Corcept Therapeutics subject to Rule 16b-3
Gary Robb over two months ago via Macroaxis 
Corcept Therapeutics exotic insider transaction detected
Sean Maduck over three months ago via Macroaxis 
Acquisition by Sean Maduck of 50000 shares of Corcept Therapeutics subject to Rule 16b-3
Gary Robb over three months ago via Macroaxis 
Corcept Therapeutics exotic insider transaction detected
Gary Robb over three months ago via Macroaxis 
Bona fide gift to Gary Robb of 637 shares of Corcept Therapeutics subject to Section 16
Guyer William over three months ago via Macroaxis 
Acquisition by Guyer William of 100000 shares of Corcept Therapeutics subject to Rule 16b-3
Hunt Hazel over six months ago via Macroaxis 
Exercise or conversion by Hunt Hazel of 40000 shares of Corcept Therapeutics subject to Rule 16b-3

Corcept Therapeutics Predictive Daily Indicators

Corcept Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Corcept Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Corcept Therapeutics Forecast Models

Corcept Therapeutics time-series forecasting models is one of many Corcept Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Corcept Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Corcept Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Corcept Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Corcept shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Corcept Therapeutics. By using and applying Corcept Stock analysis, traders can create a robust methodology for identifying Corcept entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 34.01  28.80 
EBITDA Margin 0.35  0.38 
Gross Margin 0.99  1.09 
Profit Margin 0.31  0.33 
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. Corcept Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 238 people.

Current Corcept Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Corcept analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Corcept analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
25.5Hold4Odds
Corcept Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Corcept analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Corcept stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Corcept Therapeutics, talking to its executives and customers, or listening to Corcept conference calls.
Corcept Analyst Advice Details

Corcept Stock Analysis Indicators

Corcept Therapeutics stock analysis indicators help investors evaluate how Corcept Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Corcept Therapeutics shares will generate the highest return on investment. By understating and applying Corcept Therapeutics stock analysis, traders can identify Corcept Therapeutics position entry and exit signals to maximize returns.
Quick Ratio5.31
Fifty Two Week Low15.83
Revenue Growth15.30%
Average Daily Volume Last 10 Day586.96k
Shares Short Prior Month16.11M
Average Daily Volume In Three Month804.44k
Earnings Growth31.10%
Shares Percent Shares Out17.06%
Earnings Quarterly Growth23.30%
Gross Margins98.56%
Forward Price Earnings26.03
Short Percent Of Float26.47%
Float Shares86.38M
Fifty Two Week High29.93
Fifty Day Average23.78
Enterprise Value To Ebitda16.38
Two Hundred Day Average21.75
Enterprise Value To Revenue5.62
Continue to Trending Equities. Note that the Corcept Therapeutics information on this page should be used as a complementary analysis to other Corcept Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Corcept Stock analysis

When running Corcept Therapeutics price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.14
Market Capitalization
3.1 B
Quarterly Revenue Growth YOY
0.13
Return On Assets
0.15
Return On Equity
0.23
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Corcept Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.